HOME >> BIOLOGY >> NEWS
McGill researchers shed light on formation of carcinogen in food

Furan, a potentially dangerous chemical has been found by Health Canada and the U.S. Food and Drug Administration (FDA) in processed foods, especially canned or bottled foods. A new study by McGill researchers Dr. Varoujan Yaylayan and graduate student Carolina Perez Locas explains the presence of this chemical in a wide range of food products

The study, published in the October, 2004 issue of Journal of Agricultural and Food Chemistry, shows how food-based amino acids and sugars break down when heated to produce furan. It also identifies other food components, such as vitamin C and polyunsaturated fatty acids, which may produce furan as an unwanted by-product of cooking, bottling or canning food products.

"Furan and its derivatives sometimes form when amino acids or sugars are broken down by the heat of cooking," explains Dr. Yaylayan. "Normally, furan is a volatile chemical which tends to quickly evaporate. However, when it cannot escape for some reason, for example if it is in sealed cans or jars, then it remains present in the food for some time."

While traces of furan and furan-containing products have been found in some processed and cooked products, especially canned and bottled foods, there's no reason for consumers to change their shopping habits according to government health agencies. The quantities of furan in foods are well below what is considered dangerous.

Although furans have been linked to cancer in experimental animals, there is no direct evidence that furans are human carcinogens.

"Even so," says Dr. Yaylayan, "food companies and government agencies are keeping a close eye on the situation. It's important to know exactly what chemicals are present in food, and to understand how they form during processing."


'"/>

Contact: Christine Zeindler
christine.zeindler@mcgill.ca
514-398-6754
McGill University
2-Feb-2005


Page: 1

Related biology news :

1. A study by the MUHC and McGill University opens a new door to understanding cancer
2. MUHC and McGill scientists identify gene for debilitating vitamin B12 disease
3. McGill researcher looks at the genetics behind cheese
4. Innovative tagging technique may help researchers better protect fish stocks
5. Penn researchers discover how key protein stops inflammation
6. ASU researchers partner with UOP to make biofuel for military jets a reality
7. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
8. Penn researchers discover pathway that eliminates genetic defects in red blood cells
9. U-M researchers find family of on switches that cause prostate cancer
10. 2007 EURYI: 20 young researchers to receive Nobel Prize-sized awards for breakthrough ideas
11. Pets could be source of multiresistant bacteria infections in humans, MU researchers investigate

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: McGill researchers shed light formation carcinogen food

(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... CT ., Aug. 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces it has joined The Smart Card Alliance and ... Smart Card Alliance and the Smart Card Alliance Latin ... visibility to industry peers and thought leaders promoting adoption ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:8/28/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... the development of autologous cell therapies, today reported ... 2015, corporate highlights, and near-term milestones.  The company,s ... www.sedar.com ,  www.edgar.com and at ... to launch its RCS-01 treatment for aging and ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas ... investment firms and animal health companies to hear from animal health companies with ... have also received licensing agreements or distribution contracts. This meeting is one ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
Cached News: